Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model

Shock

Volumn 32, Issue 3, 2009, Pages 332-339

  Mondello, Stefania ^a   Mazzon, Emanuela ^a   Di Paola, Rosanna ^a   Crisafulli, Concetta ^a   Mondello, Paolo ^a   Buemi, Michele ^a   Aloisi, Carmelo ^a   Cuzzocrea, Salvatore ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cytokines; Peritoneal fibrosis; Thalidomide

Indexed keywords

3 NITROTYROSINE; CHLORHEXIDINE GLUCONATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MYELOPEROXIDASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PERITONITIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SCLEROSING ENCAPSULATING PERITONITIS;

ANIMALS; ANTI-INFECTIVE AGENTS; BLOTTING, WESTERN; CHLORHEXIDINE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; I-KAPPA B PROTEINS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PERITONITIS; PEROXIDASE; POLY ADENOSINE DIPHOSPHATE RIBOSE; RATS; THALIDOMIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 69549101714     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181994974     Document Type: Article

References (46)

1. Honda K, Nitta K, Horita S, Yumura W, Nihei H: Morphological changes in the peritoneal vasculature of patients on capd with ultrafiltration failure. Nephron 72:171-176, 1996. (Pubitemid 26035372)
2. Zweers MM, Struijk DG, Smit W, Krediet RT: Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up. J Lab Clin Med 137:125-132, 2001. (Pubitemid 32116955)
3. Margetts PJ, Bonniaud P: Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 23:530-541, 2003. (Pubitemid 37527296)
4. Stompor T, Zdzienicka A, Motyka M, Dembinska-Kiec A, Davies SJ, Sulowicz W: Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport. Perit Dial Int 22:670-676, 2002. (Pubitemid 36131496)
5. Yeh TS, Ho YP, Huang SF, Yeh JN, Jan YY, Chen MF: Thalidomide salvages lethal hepatic necroinflammation and accelerates recovery from cirrhosis in rats. J Hepatol 41:606-612, 2004.
6. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr: Inhibition of NFkappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382-22387, 2001. (Pubitemid 37410912)
7. Lv P, Luo HS, Zhou XP, Xiao YJ, Paul SC, Si XM, Zhou YH: Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res 38:15-27, 2007. (Pubitemid 44914017)
8. Lv P, Luo HS, Zhou XP, Chireyath Paul S, Xiao YJ, Si XM, Liu SQ: Thalidomide prevents rat liver cirrhosis via inhibition of oxidative stress. Pathol Res Pract 202:777-788, 2006. (Pubitemid 44575894)
9. Meierhofer C, Dunzendorfer S, Wiedermann CJ: Theoretical basis for the activity of thalidomide. BioDrugs 15:681-703, 2001.
10. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675-1680, 1993. (Pubitemid 23146134)
11. Mishima Y, Miyazaki M, Abe K, Ozono Y, Shioshita K, Xia Z, Harada T, Taguchi T, Koji T, Kohno S: Enhanced expression of heat shock protein 47 in rat model of peritoneal fibrosis. Perit Dial Int 23:14-22, 2003. (Pubitemid 36348155)
12. Mazzon E, Muia C, Di Paola R, Genovese T, De Sarro A, Cuzzocrea S: Thalidomide treatment reduces colon injury induced by experimental colitis. Shock 23:556-564, 2005. (Pubitemid 40677430)
13. Mullane KM, Kraemer R, Smith B: Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 14:157-167, 1985. (Pubitemid 15241170)
14. Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Esposito E, Bramanti P, Cuzzocrea S: TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome. Shock 29:32-41, 2008.
15. Cuzzocrea S, Di Paola R, Mazzon E, Crisafulli C, Genovese T, Muia C, Abdelrahman M, Esposito E, Thiemermann C: Glycogen synthase kinase 3beta inhibition reduces the development of nonseptic shock induced by zymosan in mice. Shock 27:97-107, 2007. (Pubitemid 44968017)
16. Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GI: What really happens to people on long-term peritoneal dialysis? Kidney Int 54:2207-2217, 1998.
17. Slingeneyer A: Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis. Contrib Nephrol 57:239-247, 1987.
18. Topley N: The host's initial response to peritoneal infection: the pivotal role of the mesothelial cell. Perit Dial Int 15:116-117, 1995.
19. Yang AH, Chen JY, Lin YP, Huang TP, Wu CW: Peritoneal dialysis solution induces apoptosis of mesothelial cells. Kidney Int 51:1280-1288, 1997.
20. Hawley CM, Wall DR, Johnson DW, Campbell SB, Griffin AD, Rigby RJ, Petrie JJ: Recovery of gastrointestinal function after renal transplantation in a patient with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis. Am J Kidney Dis 26:658-661, 1995.
21. Mori Y, Matsuo S, Sutoh H, Toriyama T, Kawahara H, Hotta N: A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 30:275-278, 1997. (Pubitemid 27330346)
22. Junor BJ: Continuous ambulatory peritoneal dialysis. Scott Med J 31:69-71, 1986.
23. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S, Margolin S: Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol 47:287-291, 1995.
24. Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S: An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 16:1262-1266, 2001. (Pubitemid 32547385)
25. Gotloib L, Wajsbrot V, Shostak A, Kushnier R: Morphology of the peritoneum: effect of peritoneal dialysis. Perit Dial Int 15:9-11, 1995.
26. Bunke CM, Brier ME, Golper TA: Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the network 9 peritonitis study. Kidney Int 52:524-529, 1997.
27. Wettstein AR, Meagher AP: Thalidomide in Crohn's disease. Lancet 350:1445-1446, 1997.
28. McBride WG: The teratogenic action of drugs. Med J Aust 2:689-692, 1963.
29. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 117:1278-1287, 1999.
30. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E: The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol 25:964-969, 1998. (Pubitemid 28210563)
31. Agarwal S, Deschner J, Long P, Verma A, Hofman C, Evans CH, Piesco N: Role of NF-kappaB transcription factors in antiinflammatory and proinflammatory actions of mechanical signals. Arthritis Rheum 50:3541-3548, 2004. (Pubitemid 39488679)
32. Bowie A, O'Neill LA: Oxidative stress and nuclear factor-kappab activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59:13-23, 2000.
33. Genovese T, Mazzon E, Esposito E, Di Paola R, Caminiti R, Meli R, Bramanti P, Cuzzocrea S: Effect of thalidomide on signal transduction pathways and secondary damage in experimental spinal cord trauma. Shock 30:231-240, 2008.
34. Malleo G, Mazzon E, Genovese T, Di Paola R, Muia C, Crisafulli C, Siriwardena AK, Cuzzocrea S: Effects of thalidomide in a mouse model of cerulein-induced acute pancreatitis. Shock 29:89-97, 2008.
35. Mazzon E, Cuzzocrea S: Thalidomide treatment reduces the alteration of paracellular barrier function in mice ileum during experimental colitis. Shock 25:515-521, 2006. (Pubitemid 43755923)
36. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 342:1350-1358, 2000. (Pubitemid 30408720)
37. Lin CY, Chen WP, Yang LY, Chen A, Huang TP : Persistent transforming growth factor-beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence. Am J Nephrol 18:513-519, 1998. (Pubitemid 28562906)
38. Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T: Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 61:570-578, 2002. (Pubitemid 34102598)
39. Jorres A, Ludat K, Sander K, Dunkel K, Lorenz F, Keck H, Frei U, Gahl GM: The peritoneal fibroblast and the control of peritoneal inflammation. Kidney Int Suppl 56:22-27, 1996.
40. Combet S, Van Landschoot M, Moulin P, Piech A, Verbavatz JM, Goffin E, Balligand JL, Lameire N, Devuyst O: Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis. J Am Soc Nephrol 10:2185-2196, 1999. (Pubitemid 29453497)
41. Pollock C: Pathogenesis of peritoneal sclerosis. Int J Artif Organs 28:90-96, 2005.
42. Murthy KG, Xiao CY, Mabley JG, Chen M, Szabo C: Activation of poly(ADP-ribose) polymerase in circulating leukocytes during myocardial infarction. Shock 21:230-234, 2004.
43. Szabo A, Hake P, Salzman AL, Szabo C: 3-Aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase, improves hemodynamics and prolongs survival in a porcine model of hemorrhagic shock. Shock 10:347-353, 1998. (Pubitemid 128463273)
44. Fukuoka N, Sugiyama H, Inoue T, Kikumoto Y, Takiue K, Morinaga H, Nakao K, Maeshima Y, Asanuma M, Wang DH: Increased susceptibility to oxidant-mediated tissue injury and peritoneal fibrosis in acatalasemic mice. Am J Nephrol 28:661-668, 2008. (Pubitemid 351832454)
45. Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y: Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 22:2838-2848, 2007. (Pubitemid 350093438)
46. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, Harada T, Ozono Y, Koji T, Kohno S: TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 66:1677-1685, 2004. (Pubitemid 39298405)